LUMO News and Press, Lumos Pharma Inc. From 03/01/23

Lumos Pharma press release ( NASDAQ: LUMO ): FY GAAP EPS of -$3.71 misses by $0.07 . Revenue of $1.52M (+560.9% Y/Y) beats by $0.38M . Lumos Pharma ended the year on December 31, 2022, with cash, cash equivalents, and short-term investments totaling $67.4 mil...

-- Patient Enrollment Completed in OraGrowtH210 and OraGrowtH212 Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected Q4 2023 -- -- Additional Data from OraGrowtH Trials to be Presented at IMPE 2023 -- -- Conference Call Scheduled for Today at 4:30 ET -- ...

Lumos Pharma ( NASDAQ: LUMO ) is scheduled to announce FY earnings results on Wednesday, March 1st, after market close. The consensus EPS Estimate is -$3.62 and the consensus Revenue Estimate is $1.14M (compared to $0.23M in year ago quarter). For further details see: Lu...

Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled Primary Outcome Data for Both OraGrowtH Trials Expected 4Q 2023 AUSTIN, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therap...

AUSTIN, Texas, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2022 financial results ...

AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 12 th A...

AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6 th to review the Company’s interim da...

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of int...

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present a...

Lumos Pharma ( NASDAQ: LUMO ), a biotech focused on rare diseases, announced Monday that its lead asset, LUM-201 met expectations in an interim analysis of two Phase 2 trials for Pediatric Growth Hormone Deficiency (PGHD). The OraGrowtH210 and OraGrowtH212 trials were design...